chronic pulmonary aspergillosis
Conditions
Interventions
None listed
Sponsors
Nagasaki evaluation organization for clinical interventions
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient who was diagnosed with CPA according to following criteria and was registered in previously conducted clinical study as NEOCI-0001(UMIN 000001786) or NEOCI-0002 (UMIN 000002236). (1) Chronic respiratory symptom or systemic symptom; i.e. the existence of at least one of the symptoms of fever, weight loss, sputum, cough, hemoptysis, fatigue, and dyspnea (2) New infiltrates or cavity formation or expansion of pre-existing cavities with or without peri-cavitary infiltrates and adjacent pleural thickening in last six months. (3) At least one positive result of serologic tests including Aspergillus antigen test, antibody test and/or any positive evidences if existence of Aspergillus species by molecular diagnosis, culture positive and pathological findings. (4) Positive findings of at least one of the inflammation markers such as white blood cell (WBC) counts, value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). (5) Non-improvement of symptoms to at least 3 days-administration of wide-broad systemic antibiotics (exclusion of respiratory infection with CPA like clinical condition).
Exclusion criteria
Exclusion criteria: Patient who had not been registered to NEOCI-0001(UMIN 000001786) or NEOCI-0002 (UMIN 000002236)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Prognosis of CPA: Calculate one year and two year survival rate 2) Maintenance therapy after acute-phase treatment | — |
Countries
Japan
Contacts
Public ContactKoichi Izumikawa
Nagasaki University Graduate School of Biomedical Sciences Department of Molecular Microbiology and Immunology
Outcome results
None listed